Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07409636 · ClinicalTrials.gov registry record
A Study to Assess the Real-World Effectiveness of Inclisiran and PCSK9 mAbs in Chinese Hypercholesterolemia Adult Patients
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 11,991
- Enrollment target
NCT07409636 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 11,991 participants.
The verdict
NCT07409636 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 11,991 participants
- Enrollment target
Study Summary
The purpose of this study was to describe the effectiveness of inclisiran and proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) in the real-world setting in China. Data for this study was obtained from three regional electronic health record (rEHR) databases and included patients who met the enrollment requirements during the study identification period (October 1, 2023 to June 30, 2024) who had used either inclisiran or PCSK9 mAb for the first time. The retrospective data up to the date of ethics committee (EC) approval was extracted from multiple rEHR databases to generate study-specific datasets supporting this study on respective secure data analysis platforms. Due to the requirements of data security policies, the patient-level data from rEHR databases could not be transferred out of the secure platform. Thus, independent analysis based on data from each of the three databases was performed separately and meta-analysis was conducted to integrate one result of all independent data analyses.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11,991 participants |
| Start Date | 2025-01-23 |
| Est. Completion | 2025-12-22 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07409636
The ClinicalTrials.gov registry entry for NCT07409636 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 11,991 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07409636 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07409636 about?
NCT07409636 is a clinical study titled "A Study to Assess the Real-World Effectiveness of Inclisiran and PCSK9 mAbs in Chinese Hypercholesterolemia Adult Patients". The purpose of this study was to describe the effectiveness of inclisiran and proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) in the real-world setting in China. Data for this study was obtained from three regional electronic health record (rEHR) databases and inc...
What is the current status of trial NCT07409636?
This trial is currently completed. The enrollment target is 11,991 participants. The study started on 2025-01-23. Estimated completion is 2025-12-22.
Who is sponsoring clinical trial NCT07409636?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.